Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-58

First 58 Last

Share
Profile

Follow
ddwn

12,519 Posts.

3391

17/02/21

16:56

Post #: 51087826
Share

Originally posted by DocMcstuffins: ↑

So they also only really mention the blood results of patient one, because patient 2s blood test improvements (specifically the BNP) don't really correspond to the treatments.

If you look at the improvements in inflammatory markers, BNP, renal function, they all follow a general trend of improvement that isn't obviously related to the infusions.

Below is the BNP of patient two, who they decide not to discuss during the discussion.

They also need to clarify when in the day the children got the treatments, and when they had blood tests.

Because, at least in Australia, they'd get the tests that day then get the infusions. And if that's the case these results are even less significant, because the BNP trend is obviously in place prior to the therapy in the one child they brought up.

Not really convinced, TBH. This is not something that would convince a physician to use this therapy. As usual, need more data.

The profound hypertension is absolutely something they glossed over as well, and it's funny they say there's no adverse effects and go on to mention one kid is still on antihypertensives.

Again, steroids can cause hypertension too. So we don't know if this is caused by remestemcell. I'd be interested to know if this is common when treating these patients with standard of care

IMO DYOR

Expand

This is part of an EAP, so I'm not too sure what you were expecting.

Of course the data is not complete and hence a trial is required.

But, it has gone beyond talk and heresay, it's been published for public scrutiny - that's an important step

MSB Price at posting: $2.65 Sentiment: Buy Disclosure: Held
21 Upvote

0 Great analysis

Reply

Top Stories

ALR

Altair Minerals hits high-grade copper and gold at Wee MacGregor, QLD

PTR

Petratherm adds $1.6 to the piggybank ahead of SA titanium drilling program

SNG

Siren Gold boosts antimony resource by 66% to 14.5Kt at Auld Creek, NZ

WMG

Western Mines identifies 2 high-grade zones at Mulga Tank in WA

WR1

Winsome scoping study proposes low-cost operation for Adina lithium project